DJIA 17,164.95 -251.90 -1.45%
NASDAQ 4,635.24 -48.17 -1.03%
S&P 500 1,994.99 -26.26 -1.30%
market minute promo

43.44 -0.21 (-0.48%)

REAL-TIME: Last trade at

company name or ticker

Recent Quotes

ENTA $43.44 -0.48%
1D 1W 3M 6M 1Y 2Y 3Y
Today's Open $43.50
Previous Close $43.65
Daily Range $43.10 - $44.43
52-Week Range $31.22 - $52.58
Market Cap $808.2M
P/E Ratio 24.25
Dividend (Yield) $0.00 (0.0%)
Volume 445,952
Average Daily Volume 417,377
Current FY EPS $9.15



Enanta Pharmaceuticals, Inc. (ENTA) Description

Enanta Pharmaceuticals, Inc. Website:

News & Commentary

3 Biotech Stocks With a Higher Profit Margin Than Gilead Sciences, Inc.

Gilead's nearly 46% profit margin is among the best in the biotech sector. However, these three biotech stocks currently have Gilead beat.

White House Budget To Support Biotech Rally

Insider Trading Alert - ENTA, ATSG And SWN Traded By Insiders

I'm Expecting Some Very Positive News Flow From Gilead

Insider Trading Alert - ENTA, HSNI And MMLP Traded By Insiders

Commit To Purchase Enanta Pharmaceuticals At $42, Earn 13.5% Annualized Using Options

The Hepatitis C Drug Developer That Crushed Gilead Sciences, Inc. in 2014 (Hint: It's Not AbbVie)

Gilead Sciences Sovaldi was a superstar in 2014, helping Gilead to nearly a 40% year-to-date return. However, one hepatitis C drug developer has delivered 700% better returns to shareholders this year!

Enanta Pharmaceuticals (ENTA) Jumps: Stock Rises 10.1% - Tale of the Tape

Enanta Pharmaceuticals (ENTA) In A Perilous Reversal

AbbVie Inc. Throws First Punch in Hep C Price War With Gilead Sciences, Inc.

Express Scripts makes AbbVie's Viekira Pak its exclusive hepatitis C drug, excluding Gilead's Harvoni.

See More ENTA News...